CClinicalTrials.gg
Sign In
RecruitingNCT07488013Updated Mar 23, 2026

The Impact of Early Regular Diet vs Conventional Clear Fluids Regimen on Colorectal Anastomosis

An interventional study of regular diet and Clear fluids in Colorectal Anastomosis, sponsored by Ayman Alayat. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Ayman Alayat · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2025, registered Mar 2026).
  • Started Jul 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the effect of early regular feeding protocol vs conventional clear fluids regimen as per ERAS protocols in patients undergoing colorectal anastomosis. The main questions it aims to answer are:

  1. Food tolerance and return of normal bowel Habbits.
  2. Rate of Anastomotic leakage
  3. Length of hospital stay
02

Conditions studied

  • Colorectal Anastomosis

Keywords

  • colorectal anastomosis
  • ERAS protocol
  • Early feeding
03

In context

Lead sponsor

This is the only study on the registry with Ayman Alayat as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with a single, primary large bowel anastomosis

Exclusion criteria

Exclusion Criteria:

  • Patients with large bowel anastomosis and proximal diversion.
  • Patients with severe systemic illnesses or comorbidities that may impact surgical outcomes or dietary tolerance (e.g., severe heart failure, renal failure, liver failure).
  • Patients who require post-operative intensive care unit (ICU) admission or mechanical ventilation
  • Patients with pre-existing conditions that may affect gastrointestinal function or nutrient absorption (e.g., Crohn's disease, malabsorption syndromes).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Early regular feeding

    Early regular feeding will be initiated within the first 12 hours post-operatively.

    Behavioral: regular diet

  • Active comparator
    Conventional

    Clear fluids will be initiated within the first 12 hours post-operatively and then upgraded gradually as the patient regains normal bowel motions

    Behavioral: Clear fluids

Interventions

  • Behavioralregular diet

    Regular diet will be initiated within the first 12 hours post-operatively

  • BehavioralClear fluids

    Clear fluids will be initiated post-operatively and then gradually updated to regular diet as the patient regains his normal motions

06

What researchers measure

Primary outcomes

  1. Duration of post-operative ileus

    Duration till the passage of flatus and stool will be documented

    Time frame: from the beginning of the post-operative period up to 30 days

  2. Rate of anastomotic leakage

    Time frame: from the beginning of the post-operative period up to 30 days

Secondary outcomes

  1. Length of hospital stay

    Time frame: up to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07488013
Lead sponsor
Ayman Alayat
Responsible party
Ayman Alayat (Principal Investigator, Kasr El Aini Hospital) — Sponsor-investigator
First posted
Mar 23, 2026
Start date
Jul 1, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Mar 23, 2026

Study contacts

Tarek Salem Mabrouk
Contact
tareksalem2018011@gmail.com
00201143307034

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion